Nearly 2.4 million people in the United States have a substance use disorder (SUD) related to prescription opioids. Approximately half a million people have a SUD related to heroin and fentanyl. There has been a significant increase in hospitalizations for opioid misuse. As a result, the government has introduced new state-funded programs and legislation to prevent overdoses and improve treatment outcomes. The U.S. Food and Drug Administration has approved three different medications to treat opioid addiction: buprenorphine, methadone, and naltrexone. All three are collectively referred to as medication-assisted treatment (MAT). Research shows a combination of medication and therapy is often the most successful approach to treating opioid addiction.
Buprenorphine is used in medication-assisted treatment (MAT) to help people quit their use of illicit opioids. Approved for clinical use in October 2002 by the Food and Drug Administration (FDA), buprenorphine represents the latest advancement in medication-assisted treatment (MAT). Medications such as buprenorphine, combined with behavioral counseling, provide a comprehensive approach to treating opioid addiction. When taken as prescribed, buprenorphine is safe and effective.